Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM)
- Author
- Jan Van Droogenbroeck, Philip Vlummens (UGent) , Noa Lavi, Ka Lung Wu, Jiayu Fu, Huaibao Feng, Robin L Carson, Wendy Crist, Jordan Schecter and Yael Cohen
- Organization
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8600149
- MLA
- Van Droogenbroeck, Jan, et al. “Randomized, Open-Label, Phase 2/3 Study of Daratumumab (DARA) with or without JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma (RRMM).” JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 15, suppl., 2018, doi:10.1200/JCO.2018.36.15_suppl.TPS8057.
- APA
- Van Droogenbroeck, J., Vlummens, P., Lavi, N., Wu, K. L., Fu, J., Feng, H., … Cohen, Y. (2018). Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM). JOURNAL OF CLINICAL ONCOLOGY, 36(15, suppl.). https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS8057
- Chicago author-date
- Van Droogenbroeck, Jan, Philip Vlummens, Noa Lavi, Ka Lung Wu, Jiayu Fu, Huaibao Feng, Robin L Carson, Wendy Crist, Jordan Schecter, and Yael Cohen. 2018. “Randomized, Open-Label, Phase 2/3 Study of Daratumumab (DARA) with or without JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma (RRMM).” In JOURNAL OF CLINICAL ONCOLOGY. Vol. 36. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS8057.
- Chicago author-date (all authors)
- Van Droogenbroeck, Jan, Philip Vlummens, Noa Lavi, Ka Lung Wu, Jiayu Fu, Huaibao Feng, Robin L Carson, Wendy Crist, Jordan Schecter, and Yael Cohen. 2018. “Randomized, Open-Label, Phase 2/3 Study of Daratumumab (DARA) with or without JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma (RRMM).” In JOURNAL OF CLINICAL ONCOLOGY. Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.TPS8057.
- Vancouver
- 1.Van Droogenbroeck J, Vlummens P, Lavi N, Wu KL, Fu J, Feng H, et al. Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM). In: JOURNAL OF CLINICAL ONCOLOGY. 2018.
- IEEE
- [1]J. Van Droogenbroeck et al., “Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM),” in JOURNAL OF CLINICAL ONCOLOGY, 2018, vol. 36, no. 15, suppl.
@inproceedings{8600149, articleno = {{abstract TPS8057}}, author = {{Van Droogenbroeck, Jan and Vlummens, Philip and Lavi, Noa and Wu, Ka Lung and Fu, Jiayu and Feng, Huaibao and Carson, Robin L and Crist, Wendy and Schecter, Jordan and Cohen, Yael}}, booktitle = {{JOURNAL OF CLINICAL ONCOLOGY}}, issn = {{0732-183X}}, language = {{eng}}, number = {{15, suppl.}}, title = {{Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM)}}, url = {{http://doi.org/10.1200/JCO.2018.36.15_suppl.TPS8057}}, volume = {{36}}, year = {{2018}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: